Table 1.
Patient and tumor characteristics for all patients stratified by pathologic stage subgroup
| All (n = 2795) | Organ confined (n = 1617) | Extravesical (n = 545) | Node positive (n = 633) | |
|---|---|---|---|---|
| Decade of cystectomy, n (%) | ||||
| 1970–1980 | 117 (4.2) | 74 (4.6) | 10 (1.8) | 33 (5.2) |
| 1980–1990 | 495 (17.7) | 296 (18.3) | 105 (19.3) | 94 (14.8) |
| 1990–2000 | 567 (20.3) | 299 (18.5) | 126 (23.1) | 142 (22.4) |
| 2000–2010 | 884 (31.6) | 505 (31.2) | 182 (33.4) | 197 (31.1) |
| 2010–2020 | 732 (26.2) | 443 (27.4) | 122 (22.4) | 167 (26.4) |
| Age (yr) | ||||
| Median | 68 | 67 | 70 | 68 |
| Min-max | 23–95 | 27–95 | 23–93 | 37–94 |
| Gender, n (%) | ||||
| Female | 574 (20.5) | 302 (18.7) | 118 (21.7) | 154 (24.3) |
| Male | 2221 (79.5) | 1315 (81.3) | 427 (78.3) | 479 (75.7) |
| Radiation, n (%) | ||||
| Neoadjuvant | 152 (5.4) | 98 (6.1) | 20 (3.7) | 34 (5.4) |
| Adjuvant | 20 (0.7) | 4 (0.2) | 7 (1.3) | 9 (1.4) |
| Chemotherapy, n (%) | ||||
| Neoadjuvant | 334 (11.9) | 183 (11.3) | 62 (11.4) | 89 (14.1) |
| Adjuvant | 506 (18.1) | 59 (3.6) | 131 (24.0) | 316 (49.9) |
| Smoker, n (%) | ||||
| Current | 543 (19.4) | 289 (17.9) | 110 (20.2) | 144 (22.7) |
| Never | 626 (22.4) | 359 (22.2) | 118 (21.7) | 149 (23.5) |
| Previous | 1528 (54.7) | 908 (56.2) | 306 (56.1) | 314 (49.6) |
| Grade, n (%) | ||||
| 0 | 69 (2.5) | 64 (4) | 4 (0.7) | 1 (0.2) |
| 1 | 2424 (86.7) | 1272 (78.7) | 540 (99.1) | 612 (96.7) |
| 2 | 302 (10.8) | 281 (17.4) | 1 (0.2) | 20 (3.2) |
| Lymphovascular invasion, n (%) | ||||
| Positive | 2004 (71.7) | 1447 (89.5) | 352 (64.6) | 205 (32.4) |
| Negative | 791 (28.3) | 170 (10.5) | 193 (35.4) | 428 (67.6) |
| Survival status, n (%) | ||||
| Deceased | 1620 (58.0) | 794 (49.1) | 349 (64.0) | 477 (75.4) |
| Deceased by disease | 701 (25.1) | 203 (12.6) | 171 (31.4) | 327 (51.7) |
| Censored | 1175 (42.0) | 823 (50.9) | 196 (36.0) | 156 (24.6) |
| Progressed | 812 (29.1) | 259 (16.0) | 191 (35.0) | 362 (57.2) |
| Developed progression, n (%) | ||||
| Urethra | 74 (2.6) | 49 (3.0) | 17 (3.1) | 8 (1.3) |
| Pelvis | 213 (7.6) | 49 (3.0) | 67 (12.3) | 97 (15.3) |
| Lymph node (regional) | 97 (3.5) | 33 (2.0) | 11 (2.0) | 53 (8.4) |
| Lymph node (distal) | 76 (2.7) | 19 (1.2) | 9 (1.7) | 48 (7.6) |
| Peritoneum | 59 (2.1) | 13 (0.8) | 9 (1.7) | 37 (5.8) |
| Adrenal gland | 30 (1.1) | 5 (0.3) | 9 (1.7) | 16 (2.5) |
| Liver | 198 (7.1) | 53 (3.3) | 47 (8.6) | 98 (15.5) |
| Bone | 259 (9.3) | 67 (4.1) | 67 (12.3) | 125 (19.7) |
| Brain | 47 (1.7) | 15 (0.9) | 13 (2.4) | 19 (3.0) |
| Lung | 228 (8.2) | 81 (5.0) | 59 (10.8) | 88 (13.9) |
| Retroperitoneum | 171 (6.1) | 48 (3.0) | 22 (4.0) | 101 (16.0) |
| Upper tract | 57 (2.0) | 42 (2.6) | 8 (1.5) | 7 (1.1) |
| Other | 133 (4.8) | 42 (2.6) | 27 (5.0) | 64 (10.1) |
| Total developed progressions, n (%) | ||||
| 0 | 1983 (70.9) | 1358 (84.0) | 354 (65.0) | 271 (42.8) |
| 1 | 370 (13.2) | 126 (7.8) | 88 (16.1) | 156 (24.6) |
| 2 | 223 (8.0) | 63 (3.9) | 56 (10.3) | 104 (16.4) |
| 3 | 121 (4.3) | 35 (2.2) | 32 (5.9) | 54 (8.5) |
| 4 | 52 (1.9) | 20 (1.2) | 8 (1.5) | 24 (3.8) |
| 5 | 28 (1.0) | 12 (0.7) | 5 (0.9) | 11 (1.7) |
| 6 | 11 (0.4) | 2 (0.1) | 2 (0.4) | 7 (1.1) |
| 7 | 7 (0.3) | 1 (0.1) | 0 (0) | 6 (0.9) |
The metastasis section represents the distinct number of patients who developed that particular progression, not counting multiple or repeat occurrences.